Skip to content

A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis

A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06990594
Enrollment
120
Registered
2025-05-25
Start date
2025-06-01
Completion date
2027-12-31
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The purpose of this study is to evaluate the clinical benefits of different types of total knee arthroplasty (TKA) in osteoarthritis treatment. The study aims to compare surgical outcomes, functional recovery, complication rates, and cost-effectiveness among personalized, semi-personalized, and conventional TKA in a multi-center, bidirectional cohort study.

Detailed description

This study aims to assess the performance of personalized, semi-personalized, and conventional total knee arthroplasty (TKA) procedures across different patient groups. This is a prospective cohort and controlled study involving 120 patients, including 40 in the experimental group receiving personalized TKA, 40 receiving semi-personalized TKA, and 40 in the control group receiving conventional TKA. Participants will be 50-80 years old, diagnosed with end-stage knee osteoarthritis, post-traumatic arthritis, avascular necrosis, inflammatory arthritis, or deformities requiring total knee arthroplasty. They will be followed for one year post-surgery to assess clinical outcomes.

Interventions

None listed

Sponsors

Peking University Shougang Hospital
CollaboratorOTHER
Beijing Chao Yang Hospital
CollaboratorOTHER
Beijing Tsinghua Chang Gung Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years

Inclusion criteria

1. Patients aged 50-80 years. 2. Diagnosed with end-stage knee osteoarthritis, post-traumatic arthritis, avascular necrosis, or inflammatory arthritis requiring total knee arthroplasty. 3. Willing and able to provide informed consent.

Exclusion criteria

1. History of prior knee surgery or knee replacement. 2. Severe knee deformity (valgus \>20° or varus \>15°) or instability. 3. Severe contracture (\>25° flexion contracture). 4. Undergoing total knee revision surgery. 5. Rheumatoid arthritis diagnosis. 6. BMI \>35. 7. Neuromuscular disorders affecting knee stability or gait. 8. Pregnancy or lactation. 9. Presence of significant comorbidities posing unacceptable risk. 10. Active or recent severe infections or malignancy. 11. History of drug or alcohol abuse in the past six months.

Design outcomes

Primary

MeasureTime frameDescription
Knee Society Score (KSS)At baseline, 6 months, and 12 months post-surgeryThe KSS is a standardized assessment tool used to evaluate knee function and pain following total knee arthroplasty. It includes an objective knee score and a functional score, measuring alignment, stability, and range of motion.

Secondary

MeasureTime frameDescription
Prosthesis Positioning and AlignmentAt baseline and 12 months post-surgery.Radiographic evaluation will assess implant positioning and limb alignment.
Functional ImprovementAt baseline, 6 months, and 12 months post-surgery.Functional improvement will be measured using SF-36 Health Survey, Knee Injury and Osteoarthritis Outcome Score (KOOS), and gait analysis.
Pain SeverityAt baseline, 6 months, and 12 months post-surgeryVisual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) will be used to assess pain levels pre- and post-surgery.
Surgical Complication RateAt 12 months post-surgery.The rate of postoperative complications including infections, deep vein thrombosis (DVT), and revision surgeries will be recorded.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026